OBJECTIVE: Few trials report event-adjudication procedures in detail. Using data from the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) study, we compared the impact on event-rates of an adjudication strategy based on systematic screening of all reported serious adverse events (SAEs) with a strategy based on investigator diagnoses. The final diagnosis was always made by a critical events committee (CEC) using standard criteria. METHODS: ACTION randomized 7665 patients with stable angina to eithernifedipine or placebo. Pre-specified events included acute or procedural myocardial infarction (MI), refractory angina, heart failure and debilitating stroke. Clinically related SAEs including in-hospital procedures were combined into episodes independent from the investigator diagnoses entered on SAE reports. All fatal episodes and those episodes suggestive of pre-specified events were adjudicated by the CEC. RESULTS: During follow-up, 17,081 episodes were reported in 5312 patients. The SAE descriptions ruled out the occurrence of a pre-specified event in 28%. The remaining 72% were adjudicated by the CEC and 616 cases of MI, 361 of refractory angina, 275 of heart failure and 190 of debilitating stroke were diagnosed (total=1442). Had adjudication by the CEC been limited to the 3924 episodes (2397 patients) that were fatal or for which the investigator had reported any of the diagnoses mentioned, 98 cases of MI, 35 of refractory angina, 81 of heart failure and 14 of debilitating stroke would have been missed (total=228). CONCLUSION: Both the diagnostic criteria used and the adjudication process determine event-rates and conclusions about treatment effects in clinical trials. Published trial reports should always state if event-adjudication was independent of the diagnoses of investigators, and if all events of interest were adjudicated or only the first one.
RCT Entities:
OBJECTIVE: Few trials report event-adjudication procedures in detail. Using data from the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) study, we compared the impact on event-rates of an adjudication strategy based on systematic screening of all reported serious adverse events (SAEs) with a strategy based on investigator diagnoses. The final diagnosis was always made by a critical events committee (CEC) using standard criteria. METHODS: ACTION randomized 7665 patients with stable angina to either nifedipine or placebo. Pre-specified events included acute or procedural myocardial infarction (MI), refractory angina, heart failure and debilitating stroke. Clinically related SAEs including in-hospital procedures were combined into episodes independent from the investigator diagnoses entered on SAE reports. All fatal episodes and those episodes suggestive of pre-specified events were adjudicated by the CEC. RESULTS: During follow-up, 17,081 episodes were reported in 5312 patients. The SAE descriptions ruled out the occurrence of a pre-specified event in 28%. The remaining 72% were adjudicated by the CEC and 616 cases of MI, 361 of refractory angina, 275 of heart failure and 190 of debilitating stroke were diagnosed (total=1442). Had adjudication by the CEC been limited to the 3924 episodes (2397 patients) that were fatal or for which the investigator had reported any of the diagnoses mentioned, 98 cases of MI, 35 of refractory angina, 81 of heart failure and 14 of debilitating stroke would have been missed (total=228). CONCLUSION: Both the diagnostic criteria used and the adjudication process determine event-rates and conclusions about treatment effects in clinical trials. Published trial reports should always state if event-adjudication was independent of the diagnoses of investigators, and if all events of interest were adjudicated or only the first one.
Authors: H M Crane; S R Heckbert; D R Drozd; M J Budoff; J A C Delaney; C Rodriguez; P Paramsothy; W B Lober; G Burkholder; J H Willig; M J Mugavero; W C Mathews; P K Crane; R D Moore; S Napravnik; J J Eron; P Hunt; E Geng; P Hsue; G S Barnes; J McReynolds; I Peter; C Grunfeld; M S Saag; M M Kitahata Journal: Am J Epidemiol Date: 2014-03-11 Impact factor: 4.897
Authors: Robin M Nance; Heidi M Crane; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Susan R Heckbert; Daniel R Drozd; William C Mathews; Elvin Geng; Peter W Hunt; Matthew J Feinstein; Richard D Moore; Priscilla Hsue; Joseph J Eron; Greer A Burkholder; Benigno Rodriguez; Michael J Mugavero; Michael S Saag; Mari M Kitahata; Joseph A C Delaney Journal: AIDS Res Hum Retroviruses Date: 2018-08-21 Impact factor: 2.205
Authors: Zoltán Vokó; Sophie de Brouwer; Jacobus Lubsen; Nicolas Danchin; Jan-Erik Otterstad; Peter H J M Dunselman; Bridget-Anne Kirwan Journal: Eur J Epidemiol Date: 2011-02-19 Impact factor: 8.082
Authors: Sumbal A Janjua; Pedro V Staziaki; Balint Szilveszter; Richard A P Takx; Thomas Mayrhofer; Orla Hennessy; Hamed A Emami; Jakob Park; Alexander Ivanov; Travis R Hallett; Michael T Lu; Javier M Romero; Steven K Grinspoon; Udo Hoffmann; Markella V Zanni; Tomas G Neilan Journal: Circ Cardiovasc Imaging Date: 2017-10 Impact factor: 7.792
Authors: Peter J Godolphin; Alan A Montgomery; Lisa J Woodhouse; Daniel Bereczki; Eivind Berge; Rónán Collins; Exuperio Díez-Tejedor; John Gommans; Kennedy R Lees; Serefnur Ozturk; Stephen Phillips; Stuart Pocock; Kameshwar Prasad; Szabolcs Szatmari; Yongjun Wang; Philip M Bath; Nikola Sprigg Journal: PLoS One Date: 2018-11-26 Impact factor: 3.240
Authors: Frank E H P van Baarle; Emma K van de Weerdt; Bram Suurmond; Marcella C A Müller; Alexander P J Vlaar; Bart J Biemond Journal: Transfusion Date: 2020-01-31 Impact factor: 3.157
Authors: Mary Farrant; J Donald Easton; Eric E Adelman; Brett L Cucchiara; William G Barsan; Holly J Tillman; Jordan J Elm; Anthony S Kim; Anne S Lindblad; Yuko Y Palesch; Wenle Zhao; Keith Pauls; Kyle B Walsh; Joan Martí-Fàbregas; Richard A Bernstein; S Claiborne Johnston Journal: JAMA Netw Open Date: 2019-09-04